Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/27127
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2030-01-01
Coleções
- IOC - Artigos de Periódicos [12835]
Metadata
Mostrar registro completo
TUBERCULOSIS IS ASSOCIATED WITH A DOWN-MODULATORY LUNG IMMUNE RESPONSE THAT IMPAIRS TH1-TYPE IMMUNITY
Autor(es)
Almeida, Alexandre S.
Lago, Patrícia M.
Boechat, Neio
Huard, Richard C.
Lazzarini, Luiz C. O.
Santos, Adalberto R.
Nociari, Marcelo
Zhu, Hongxia
Perez-Sweeney, Beatriz M.
Bang, Heejung
Ni, Quanhong
Huang, Jie
Gibson, Andrea L.
Flores, Vera C.
Pecanha, Lorena R.
Kritski, Afrânio L.
Lapa e Silva, José R.
Ho, John L.
Lago, Patrícia M.
Boechat, Neio
Huard, Richard C.
Lazzarini, Luiz C. O.
Santos, Adalberto R.
Nociari, Marcelo
Zhu, Hongxia
Perez-Sweeney, Beatriz M.
Bang, Heejung
Ni, Quanhong
Huang, Jie
Gibson, Andrea L.
Flores, Vera C.
Pecanha, Lorena R.
Kritski, Afrânio L.
Lapa e Silva, José R.
Ho, John L.
Afiliação
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA / Columbia University Medical Center,. New York-Presbyterian Hospital. Clinical Microbiology Service. New York, NY, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular Aplicada à Micobactérias. Rio de Janeiro, RJ. Brasil.
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Weill Medical College of Cornell University. Department of Public Health. Division of Biostatistics and Epidemiology. New York, NY, USA.
Weill Medical College of Cornell University. Department of Public Health. Division of Biostatistics and Epidemiology. New York, NY, USA.
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
.Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA / Columbia University Medical Center,. New York-Presbyterian Hospital. Clinical Microbiology Service. New York, NY, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular Aplicada à Micobactérias. Rio de Janeiro, RJ. Brasil.
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Weill Medical College of Cornell University. Department of Public Health. Division of Biostatistics and Epidemiology. New York, NY, USA.
Weill Medical College of Cornell University. Department of Public Health. Division of Biostatistics and Epidemiology. New York, NY, USA.
Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil / Weill Medical College of Cornell University. Department of Medicine. Division of International Medicine and Infectious Disease. New York, NY, USA.
.Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto de Doenças Torácicas. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Immune mediators associated with human tuberculosis (TB) remain poorly defined. This study quantified levels of lung immune mediator gene expression at the time of diagnosis and during anti-TB treatment using cells obtained by induced sputum. Upon comparison to patients with other infectious lung diseases and volunteers, active pulmonary TB cases expressed significantly higher levels of mediators that counteract Th1-type and innate immunity. Despite the concomitant heightened levels of Th1-type mediators, immune activation may be rendered ineffectual by high levels of intracellular (SOCS and IRAK-M) and extracellular (IL-10 and TGF-betaRII, IL-1Rn, and IDO) immune suppressive mediators. These modulators are a direct response to Mycobacterium tuberculosis as, by day 30 of anti-TB treatment, many suppressive factors declined to that of controls whereas most Th1-type and innate immune mediators rose above pretreatment levels. Challenge of human immune cells with M. tuberculosis in vitro up-regulated these immune modulators as well. The observed low levels of NO synthase-2 produced by alveolar macrophages at TB diagnosis, along with the heightened amounts of suppressive mediators, support the conclusion that M. tuberculosis actively promotes down-modulatory mediators to counteract Th1-type and innate immunity as an immunopathological strategy. Our data highlight the potential application of immune mediators as surrogate markers for TB diagnosis or treatment response.
Compartilhar